Beijing Sun-Novo Pharmaceutical Research Balance Sheet Health
Financial Health criteria checks 5/6
Beijing Sun-Novo Pharmaceutical Research has a total shareholder equity of CN¥1.0B and total debt of CN¥357.9M, which brings its debt-to-equity ratio to 34.4%. Its total assets and total liabilities are CN¥1.7B and CN¥687.5M respectively. Beijing Sun-Novo Pharmaceutical Research's EBIT is CN¥201.8M making its interest coverage ratio 53.5. It has cash and short-term investments of CN¥629.4M.
Key information
34.4%
Debt to equity ratio
CN¥357.92m
Debt
Interest coverage ratio | 53.5x |
Cash | CN¥629.37m |
Equity | CN¥1.04b |
Total liabilities | CN¥687.48m |
Total assets | CN¥1.73b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688621's short term assets (CN¥1.3B) exceed its short term liabilities (CN¥659.9M).
Long Term Liabilities: 688621's short term assets (CN¥1.3B) exceed its long term liabilities (CN¥27.6M).
Debt to Equity History and Analysis
Debt Level: 688621 has more cash than its total debt.
Reducing Debt: 688621's debt to equity ratio has increased from 5.2% to 34.4% over the past 5 years.
Debt Coverage: 688621's debt is well covered by operating cash flow (34.3%).
Interest Coverage: 688621's interest payments on its debt are well covered by EBIT (53.5x coverage).